

Neutralisierende Antikörper gegen die transmembranen Hüllproteine von Retroviren

Dissertation

zur Erlangung des akademischen Grades des
Doktors der Naturwissenschaften (Dr.rer.nat.)

eingereicht im Fachbereich Biologie, Chemie, Pharmazie
der Freien Universität Berlin

vorgelegt von

Dipl. biol. Stefan Langhammer
aus Stade

12/2005

1. Gutachter: Prof. Dr. Kurth
2. Gutachter: Prof. Dr. Mutzel

Disputation am 21.02.06

Table of contents

1. Introduction	7
1.1 Retroviruses	7
1.1.1 Gag (group specific antigens)	10
1.1.2 Pol (enzymatic enzymes)	11
1.1.3 Env (envelope glycoproteins)	12
1.1.4 Regulatory proteins	14
1.1.5 Accessory proteins	15
1.1.6 The retroviral cycle of replication	15
1.2 The interaction of the immune system with retroviral infections	17
1.2.1 The immune system is based on different ways of reaction specific for the type of pathogen	17
1.2.2 The innate immune system displays the first line of defense	17
1.2.3 The adaptive cellular immune response is important in the defense of intra-cellular pathogens	18
1.2.4 The B-cell mediated adaptive humoral immune response is important in the defense of extra-cellular pathogens	18
1.2.5 Antibody characteristics	19
1.2.6 Neutralising antibodies	21
1.2.7 The HIV-1 neutralising monoclonal antibodies 2F5 and 4E10	22
1.2.8 Neutralising antibodies in the course of FeLV infection in cats	23
1.3 Vaccine development against retroviruses	23
1.3.1 Vaccination strategies	23
1.3.2 Vaccination with recombinant proteins can provide protection from retroviral infections	24
1.3.3 FeLV is a useful model to explore the factors that should be taken into account in developing a successful HIV vaccine	25
1.4 Goals of this study-Targeting at FeLV-A and HIV-1	26

2. Materials and methods	27
2.1 Chemicals	27
2.2 Cloning and expression of recombinant proteins used for immunisations	27
2.2.1 FeLV-A p15E ectodomain	27
2.2.2 Δ ISU p15E and p15E/gp41 hybrid proteins I and II	27
2.3 Experimental animals	28
2.3.1 Immunisation of rats and goat with the FeLV-A p15E ectodomain	
2.3.2 Immunisation of rats with Δ ISU p15E and p15E/gp41 I and II hybrid proteins	28
2.3.3 Immunisation of rats with p15E and p45	
2.3.4 FeLV-A infected pet cats, immunisation of cats with p15E and p45	28
	29
2.4 Purification of antisera by p15E affinity and proteinG columns	29
2.5 Characterisation of antisera in Western blot and ELISA	29
2.6 Epitope mapping on FeLV-A p15E and HIV-1 gp41	30
2.7 Immunofluorescence on FEA cells	30
2.8 Retroviral neutralisation assays	31
2.8.1 FeLV-A neutralisation assay with FEA cells	31
2.8.2 HIV-1 and PERV virus neutralisation assays with C8166 cells	31
2.9 Determination of retroviral provirus integration by real time PCR	32
2.9.1 FeLV-A real time PCR	32
2.9.2 HIV-1 real-time PCR	32
2.9.3 PERV real-time PCR	32
2.9.4 Calculation of provirus integration and neutralisation efficiency	32
2.10 Quantification of p27 antigen and provirus load in FeLV-A infected cats	33
2.11 Generation of hybridoma cells from rat lymphocytes	33

3. Results	34
3.1 Induction of neutralising antibodies against FeLV-A p15E in rats and goat	34
3.1.1 Characterisation of the antigen	34
3.1.2 Characterisation of binding antibodies	35
3.1.3 Neutralising antibodies against p15E	36
3.1.4 Epitope mapping	36
3.1.5 p15E-specific antibodies recognise viral protein at the surface of FeLV-infected FEA cells	38
3.2 Induction of neutralising antibodies against FeLV-A ΔISU p15E-antigen improvement	39
3.2.1 Characterisation of the antigen	39
3.2.2 Characterisation of binding and neutralising antibodies	40
3.2.3 Epitope mapping	40
3.3 Comparative studies between p15E and Leucogen induced neutralising antibodies in rats	41
3.3.1 Binding antibodies specific for p15E and p45	41
3.3.2 Induction and characterisation of neutralising antibodies	44
3.3.3 Epitope mapping	45
3.4 Induction of neutralising antibodies against p15E in cats	47
3.4.1 Induction of binding antibodies specific for p15E in cats	47
3.4.2 Induction of neutralising antibodies specific for p15E in cats	48
3.4.3 Epitope mapping	48
3.4.4 Sequences homologous to the epitopes are present in endogenous retroviruses	49
3.4.5 p15E-specific antibodies recognise viral protein at the surface of FeLV-infected cells	49
3.4.6 Neutralising antibodies in the sera of FeLV-infected cats	50
3.5 Challenge studies in p15E and p45 immunised cats	52
3.5.1 Immune response of the vaccinated and control animals before challenge	52
3.5.2 Protection was induced by the TM protein p15E as well as by Leucogen	54
3.5.3 Immunisation with Leucogen, with the transmembrane envelope protein	55

p15E and with a combination of both did not result in sterilizing immunity	
3.5.4 Provirus load and virus load correlate inversely with neutralising antibodies	56
3.6 Induction of neutralising antibodies against HIV-1 gp41	58
3.6.1 Characterisation of the antigen	58
3.6.2 Characterisation of neutralising antibodies	59
3.6.1 Epitope mapping	60
3.7 Generation of monoclonal antibodies against p15E/gp41 hybrid protein I	63
3.7.1 Characterisation of monoclonal antibodies binding to the HIV-1 gp41 E2 peptide	63
4. Discussion	
4.1 Induction and characterisation of neutralising antibodies against FeLV-A p15E in different species	66
4.1.1 Immunisation with FeLV-A p15E induces neutralising antibodies in different species including cats	67
4.1.2 The humoral immune response against the transmembrane proteins of HIV, PERV and FeLV-A shows the detection of similar located epitopes	67
4.1.3 The deletion of the ISU domain from FeLV-A p15E does not improve the antigen, but maintains an identical humoral immune response as observed for immunisation with p15E	70
4.1.4 Sequences homologue to the epitopes are present as endogenous retroviral sequences in cats	71
4.1.5 Combined immunisation with FeLV-A p15E and Leucogen induces an increased response of neutralising antibodies in rats	72
4.2 FeLV-A p15E vaccine studies in cats	73
4.2.1 Immunisation with FeLV-A p15E alone can protect cats from productive infection	73
4.3 Induction of neutralising antibodies against HIV-1 gp41 in rats by immunisation with p15E/ gp41 hybrid protein I	76
5. Summary	78

6. Deutschsprachige Zusammenfassung	79
7. References	80
8. Appendix	93
9. List of publications	96
10. Acknowledgment	97

Abbreviations

aa amino acid	PCR polymerase chain reaction
AIDS Acquired Immune Deficiency Syndrom	PEG poly ethylene glycol
Amp ampicillin	PERV Porcine Endogenous Retrovirus
CBP calmodulin-binding protein	Pol Polymerase
CCR chemokine receptor for CC chemokines	POD Peroxydase
CD cluster of differentiation	RNA Ribonucleinacid
CHR C-terminal helix region	RT Reverse transcriptase
CTL cytotoxic T-cells	SCID severe combined immune deficiency
CXCR chemokine receptor for CXC-chemokines	SHIV SIV-HIV-hybride viruses
ddH₂O Aqua bidest	SIV Simian Immune Deficiency Virus
DNA Desoxyribonucleinacid	Tat Transactivator of transcription
<i>E.coli</i> Escherichia coli	TM transmembrane region
ELISA enzyme linked immunosorbent assay	UNAIDS United Nations Department of AIDS
Env envelope protein	Vif virion infectivity factor
Fab fragment antigen binding	WHO World Health Organisation
FeLV feline leukemia virus	wt Wildtyp
FIV Feline Immune Deficiency Virus	
FCS fetal calf serum	Amino acid sequences in single letter code:
ffu/ml focus forming units per milliliter	A Alanin
FP fusion peptide	C Cystein
Gag group specific antigen	D Asparaginacid
HAART highly active anti retroviral therapy	E Glutaminacid
HAT hypoxanthine-aminopterin-thymine	F Phenylalanin
HIV human immune deficiency virus	G Glycin
HTLV human T cell leukemia virus	H Histidin
Ig immunglobuline	I Isoleucin
IN Integrase	K Lysin
k_a association constant	L Leucin
k_d dissociation constant	M Methionin
kB kilo base	N Asparagin
kD kilo Dalton	P Prolin
LTR long terminal repeat	Q Glutamin
MCS multiple cloning site	R Arginin
MHC major histocompatibility complex	S Serin
MVA modified vaccinia Ankara virus	T Threonin
Nef negative factor	V Valin
NHR N-terminal helix region	W Tryptophan
NIAID National Institute of Allergy and Infectious Diseases	X optional amino acid
NIH National Institute of Health	Y Tyrosin
NMR nuclear magentic resonance,	
PBS phosphate buffered saline	Bases of nucleotide sequences:
	A Adenin
	C Cytosin
	G Guanin
	T Thymin